Status:
COMPLETED
Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast Cancer
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
Breast Neoplasm
Drug Therapy
Eligibility:
FEMALE
18-75 years
Brief Summary
The investigators want to research whether genetic polymorphisms of drug-metabolizing enzymes can be used to predict chemotherapeutic outcomes in patients with metastatic breast cancer.
Detailed Description
1. Patients evaluation On all patients a complete clinical history and physical examination is performed, including routine hematology and biochemistry analyses. Hematology and biochemistry analyses a...
Eligibility Criteria
Inclusion
- Histologically confirmed metastatic breast cancer
- Female
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- At least one measurable lesion
- Normal cardiac, hepatic, renal and bone marrow functions
- Life expectancy ≥3 months
- Discontinuity of previous chemotherapy for a minimum of 4 weeks
Exclusion
- Central nervous system metastases
- Serious or uncontrolled concurrent medical illness
- History of other malignancies
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
153 Patients enrolled
Trial Details
Trial ID
NCT01199393
Start Date
August 1 2010
End Date
May 1 2015
Last Update
July 29 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, China, 100142